Social Capital Suvretta III (DNAC) Shareholders Approve ProKidney Deal
by Marlena Haddad on 2022-07-12 at 9:21am

Social Capital Suvretta Holdings Corp. III (NASDAQ:DNAC) announced this morning that its shareholders approved its combination with drug developer ProKidney at a special meeting held yesterday afternoon.

An 8-K that was also filed this morning disclosed that 22,829,769 of DNAC ordinary shares were presented for redemption, representing 91.319% of DNAC’s trust. ProKidney received total gross proceeds of approximately $597 million from the transaction, which it expects to use to fund Phase 3 study of REACT, accelerate manufacturing scale-out, and prepare for its global commercial launch to treat patients with late-stage chronic kidney disease and at high risk of kidney failure.

The approval comes just one week after DNAC adjourned its original special meeting citing that the parties needed additional time to satisfy “conditions to closing of the Business Combination with respect to approval by The Nasdaq Capital Market of a listing application” for the combined company’s shares.

The newly formed company is named ProKidney Corp. and its shares will start trading on the Nasdaq under the symbol “PROK” today, July 12, 2022.

The parties initially announced their $1.8 billion combination on January 18. Winston-Salem, North Carolina-based ProKidney has launched Phase III trials of its REACT cellular therapy which promises to slow the progression of chronic kidney disease (CKD) and potentially regenerate tissues and function.


ADVISORS

  • Citigroup acted as sole financial advisor and capital markets advisor to ProKidney.
  • Citigroup, Morgan Stanley, Evercore, Jefferies, and UBS acted as placement agents for a portion of the PIPE.
  • BofA Securities acted as capital markets advisor to SCS.
  • Wachtell, Lipton, Rosen & Katz acted as legal advisor to SCS.
  • Davis Polk & Wardwell LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C acted as legal advisors to ProKidney.
  • Winston & Strawn LLP is serving as legal advisor to the PIPE placement agents.
Recent Posts
by Nicholas Alan Clayton on 2024-03-28 at 1:35pm

News and Rumors PR: Bannix (NASDAQ:BNIX) has provided more information on the combination with VisionWave that it announced yesterday, specifying that the imaging technology that VisionWave will acquire from GBT Technologies will primarily seek out applications in military combat scenarios and geological surveys. PR: Grove Collaborative (NYSE:GROV), which combined with Virgin Group II in June...

by Nicholas Alan Clayton on 2024-03-28 at 7:47am

At the SPAC of Dawn Fed Chair Jerome Powell has given new hints that the administration would be showing greater levels of comfort with inflation if a cut could help improve unemployment numbers. Those numbers could get an update today at 8:30 am ET to bring new jobless claims as well as final prices for...

by Nicholas Alan Clayton on 2024-03-27 at 1:31pm

News and Rumors CNBC: Former WeWork (OTC Pink:WEWKQ) founder Adam Neumann has offered to buy back control of the company for $500 million but has yet to secure the necessary financing. WeWork went public with BowX in October 2021. PR: Satellite telecom firm Spire Global (NYSE:SPIR) has signed an agreement to build and launch two...

by Nicholas Alan Clayton on 2024-03-27 at 11:38am

Bannix (NASDAQ:BNIX) has entered into a definitive agreement to combine with VisionWave Technologies for $30 million. The combined company is expected to trade on the Nasdaq once the deal is completed with an initial outside date of September 14. Transaction Overview Bannix has about $17 million in its trust after seeing 77.4% of its shares...

by Nicholas Alan Clayton on 2024-03-27 at 7:33am

At the SPAC of Dawn Much of the attention yesterday was on tracking the swings of the newly-completed Trump Media (NASDAQ:DJT) deal with the FT going as far to suggest it may “make SPACs great again.” Not all of the day’s data points were on the positive side of the ledger, however. IB Acquisition Corp....

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved